Biosecure is in the Trump administration’s hands

The Biosecure Act is now in force, but its impact remains unclear. The Trump administration has yet to reveal implementation plans or determine which Chinese companies will be subject to the law, leaving biopharma companies and Chinese contract development and manufacturing organizations to assess what the law will mean in practice.

One point already seems clear: The law is unlikely to disrupt China’s integration into the global bioeconomy or erode its competitive advantages, because it targets U.S. government procurement rather than commercial markets, and because much of the work performed by Chinese firms occurs upstream of final manufacturing, where multinationals retain flexibility to reconfigure supply chains. While the effects on CDMOs are uncertain, the Biosecure Act is not expected to impede the rise of Chinese drug developers. ...